Treatment of chronic hepatitis B with nucleos(t)ide analogues

Hepatology Research

Volumn 42, Issue 3, 2012, Pages 219-225

  Ohishi, Waka ^a   Chayama, Kazuaki ^b  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Drug resistant virus; HBV core related antigen; HBV DNA; HBV genotype; Interferon; Nucleos(t)ide analogue

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; TENOFOVIR;

DNA VIRUS; DRUG RESISTANCE; GENOTYPE; HEALTH CARE PLANNING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84857582210     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00921.x     Document Type: Review

References (35)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
2. Lai CL, Dienstag J, Schiff E etal. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
3. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-14.
4. Yokosuka O, Takaguchi K, Fujioka S etal. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 791-9.
5. Ohishi W, Chayama K. Current treatment for chronic hepatitis B in Japan. Clin J Gastroenterol 2009; 2: 325-30.
6. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 1-7.
7. Yokosuka O, Kurosaki M, Imazeki F etal. Management of hepatitis B: consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011; 41: 1-21.
8. Keeffe EB, Dieterich DT, Han SH etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-41.
9. Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
10. Kariv R, Leshno M, Beth-Or A etal. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006; 26: 445-50.
11. Chayama K, Suzuki Y, Kobayashi M etal. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-6.
12. Ohishi W, Shirakawa H, Kawakami Y etal. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. J Med Virol 2004; 72: 558-65.
13. Ohishi W, Chayama K, Kumada H. Viral kinetics in patients with chronic hepatitis B during lamivudine therapy by real-time PCR. Acta Hepatol Jpn 2002; 43: 214. (In Japanese).
14. Tanaka E, Matsumoto A, Suzuki F etal. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 2006; 26: 90-6.
15. Colonno RJ, Rose R, Baldick CJ etal. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-65.
16. Nafa S, Ahmed S, Tavan D etal. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-88.
17. Lau DT, Khokhar MF, Doo E etal. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-34.
18. Orito E, Ichida T, Sakugawa H etal. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-94.
19. Sumi H, Yokosuka O, Seki N etal. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26.
20. Sakugawa H, Nakasone H, Nakayoshi T etal. Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. J Med Virol 2002; 67: 484-9.
21. Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology 2003; 46: 408-12.
22. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
23. Wai CT, Chu CJ, Hussain M etal. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
24. Li X, Wang L, Zhong Y etal. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol 2010; 48: 4363-9.
25. Tanaka Y, Hasegawa I, Kato T etal. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 2004; 40: 747-55.
26. Kimura T, Rokuhara A, Sakamoto Y etal. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40: 439-45.
27. Rokuhara A, Tanaka E, Matsumoto A etal. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 2003; 10: 324-30.
28. Matsumoto A, Tanaka E, Minami M etal. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37: 661-6.
29. Lok AS. Drug therapy: tenofovir. Hepatology 2010; 52: 743-7.
30. Yatsuji H, Suzuki F, Sezaki H etal. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 923-31.
31. van Bömmel F, de Man RA, Wedemeyer H etal. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
32. Yatsuji H, Hiraga N, Mori N etal. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol 2007; 79: 1811-7.
33. Matsuura K, Tanaka Y, Kusakabe A etal. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: randomized controlled trial. Hepatol Res 2011; 41: 505-11.
34. Kumada H, Scientific Research Grant of Ministry of Health, Labour and Welfare. Research of hepatitis overcome urgent strategy. 2010. Research report of the standardization of viral hepatitis treatment including cirrhosis. (In Japanese).
35. Ide T, Sata M, Chayama K etal. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010; 4: 594-600.